摘要
目的分析早期2型糖尿病肾病患者血清载脂蛋白CIII(apoCIII)水平变化,探讨瑞舒伐他汀对其影响。方法 120例2型糖尿病患者分为单纯2型糖尿病组和早期糖尿病肾病组,每组60例,早期糖尿病肾病组又分为瑞舒伐他汀治疗组和未治疗组,每组30例,治疗组给予瑞舒伐他汀10 mg,每日1次口服,共24周,分别于治疗前及治疗24周时检测所有患者的血清空腹血糖(FBG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、极低密度脂蛋白(VLDL)、apoCIII水平和24 h尿微量清蛋白(MAU)水平并进行比较。结果与单纯2型糖尿病患者比较,早期糖尿病肾病患者血清apoCIII水平明显升高,差异有统计学意义(P<0.01)。早期糖尿病肾病瑞舒伐他汀治疗组经瑞舒伐他汀治疗后,TG、TC、LDL、VLDL、apoCIII及MAU水平下降,HDL水平升高,差异有统计学意义(P<0.05)。结论早期糖尿病肾病患者血清apoCIII水平明显升高,瑞舒伐他汀治疗可以改善其水平异常,有利于降低MAU。
Objective To observe the changes of serum apolipoprotein CIII in patients of type 2 diabetes mellitus complicated by early-stage diabetic nephropathy and explore Rosuvastatin′s influence. Methods 120 patients with type 2 diabetes mellitus were classified into simple diabetes mellitus group（60 cases）and early-stage diabetic nephropathy group（60 cases）,which was then equally reclassified into therapy group（30 cases）and non-therapy group（30 cases）.We administrated the therapy group Rosuvastatin Calcium,10 mg per day for 24 weeks.The levels of FBG,HbA1c,TG,TC,HDL,LDL,VLDL,apoCIII and MAU of all the patients were detected before and after therapy and compared afterwards. Results Compared with the simple diabetes mellitus group,the level of apoCIII was significantly higher in early-stage diabetic nephropathy group（P0.01）.After rosuvastatin Calcium administration,serum levels of TG,TC,LDL,VLDL and apoCIII of the therapy group were significantly decreased,while HDL level was increased（P0.05）. Conclusion The level of apoCIII was significantly higher in early-stage diabetic nephropathy of type 2 diabetic mellitus patients.Rosuvastatin Calcium can decrease apoCIII,and MAU.
出处
《中国全科医学》
CAS
CSCD
北大核心
2012年第7期764-766,共3页
Chinese General Practice
